Positron emission tomography changes in PARK1 mutation [5]

Movement Disorders

Volumn 21, Issue 1, 2006, Pages 127-130

  Perani, Daniela ^a   Garibotto, Valentina ^b   Hadjigeorgiou, George M ^c   Papadimitriou, Dimitra ^c   Fazio, Ferruccio ^b   Papadimitriou, Alexandros ^c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CARBIDOPA PLUS LEVODOPA; CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FLUOXETINE; PROTEIN PARK1; RACLOPRIDE C 11; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; BRADYKINESIA; CASE REPORT; COGNITIVE DEFECT; COMPULSION; DEPRESSION; DOPAMINERGIC SYSTEM; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; IMPULSIVENESS; IN VIVO STUDY; IRRITABILITY; LETTER; MEMORY DISORDER; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIGIDITY; VISUAL HALLUCINATION;

ADULT; ALPHA-SYNUCLEIN; BRAIN; CARBON RADIOISOTOPES; CHROMOSOME ABERRATIONS; COCAINE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; GENES, DOMINANT; HETEROZYGOTE DETECTION; HUMANS; LEWY BODY DISEASE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE; RECEPTORS, PRESYNAPTIC;

EID: 33244486311     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20691     Document Type: Letter

References (14)

1. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
2. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-6473.
3. Papadimitriou A, Veletza V, Hadjigeorgiou GM, et al. Mutated α-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 1999;52:651-654.
4. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6:279-287.
5. Lucignani G, Gobbo C, Moresco RM, et al. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in subjects with movement disorders. Nucl Med Commun 2002;23:1047-1055.
6. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21: 1034-1057.
7. Piccini P. Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol 2004;17:459-466.
8. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 2004;11:5-12.
9. Thobois S, Ribeiro MJ, Lohmann E, et al. Young-onset Parkinson disease with and without Parkin gene mutations. Arch Neurol 2003;60:713-718.
10. Samii A, Markopoulou K, Wszolek ZK, et al. PET studies of parkinsonism associated with mutation in the α-synuclein gene. Neurology 1999;53:2097-2108.
11. Kruger R, Kuhn W, Leenders KL, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001;56:1355-1362.
12. Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and pre-frontal cortex. Neurosci Biobehav Rev 2002;26:321-352.
13. Nakano K, Kayahara T, Tsutsumi T, et al. Neural circuits and functional organization of the striatum J Neurol 2000;247:V/1-V/15.
14. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24: 197-211.